A global phase 2 trial found that giving durvalumab plus chemotherapy before surgery enabled most patients with resectable or borderline resectable non-small-cell lung cancer to have an operation, with encouraging pathological complete response rates and no new safety concerns.
Phase 2 means a small trial, and “most” usually means the drug works until the insurers start asking questions.